Dr. Paul Wesley Noble, MD

Dr. Noble practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Noble's NPI, 1942286307, was assigned on December 19, 2005. Dr. Noble graduated from New York University School of Medicine in 1984. Dr. Noble's Connecticut license number on file is 036571.

Dr. Noble's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Noble's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Noble practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Noble's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Noble is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Noble's licenses on file in 5 states: Connecticut, California, North Carolina, Maryland and Colorado.

Dmand AI lists bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis among the conditions Dr. Noble treats.

CMS data shows 232 Medicare services from Dr. Noble across 3 procedure codes in 2024, for 114 Medicare patients. Medicare paid $13,625 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 114 Medicare patients who saw Dr. Noble in 2024. The largest group is 75 to 84, with 59 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Noble's median patient age at 74, with 48% women.

In 2024, Dr. Noble wrote 394 Medicare Part D claims for 59 patients. 82% of them were for generic drugs. CMS names the drug for 340 of them, across 5 drugs with 11 or more claims each, at $802,566 in total drug cost. In 2023, CMS named 246 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Noble for performance year 2024, reported as part of a group. Dr. Noble accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 176 papers to Dr. Noble, published from 2001 to 2024. 2015 was the busiest year, with 11. The most frequent topics are Idiopathic Pulmonary Fibrosis, Lung and Pulmonary Fibrosis. Dr. Noble has published most often in Am J Respir Cell Mol Biol. Dr. Noble's most frequent co-authors are Talmadge Everett King, MD, Lisa H. Lancaster, MD and Christina Eleanor Barkauskas, MD.

CMS Open Payments shows 530 general payments to Dr. Noble from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $462,777. It also lists 1 research payment totaling $1,025 in 2020.

Dr. Noble graduated from New York University School of Medicine in 1984.

Dr. Noble is in network with 7 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.